A phase II study investigating efficacy and safety of low dosage re-treatment with (177)Lu-DOTATATE (Lu-PRRT) in patients with gastroenteropancreatic neuroendocrine neoplasms who relpased after treatment with (90)Y-DOTATOC (Y-PRRT)

Trial Profile

A phase II study investigating efficacy and safety of low dosage re-treatment with (177)Lu-DOTATATE (Lu-PRRT) in patients with gastroenteropancreatic neuroendocrine neoplasms who relpased after treatment with (90)Y-DOTATOC (Y-PRRT)

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2016

At a glance

  • Drugs Octreotate-Lu-177-DOTA-Tyr-3 (Primary)
  • Indications Neuroepithelial neoplasms
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top